Search results

Vision We want to create a regionally, nationally and internationally well-known center for translational virus research at the highest level where experimental and clinical research meet in synergy. Lund University Virus Centre  Pandemics and alertness The Covid-19 pandemic has clearly demonstrated how fast viruses can become a significant threat to global health. Through national and internation

https://www.virology.lu.se/lund-university-virus-centre - 2026-05-03

Human papillomavirus (HPV) infections cause 500.000 cases of cervical cancer each year in the world (400 cases in Sweden), and 250.000 deaths (120 cases in Sweden). HPV16 is the most common cancer-associated HPV type. The majority of all HPV16 infections is cleared by the host but a fraction persists that may cause cancer. The full life cycle of HPV16 requires cell proliferation at the early stage

https://www.virology.lu.se/molecular-virology - 2026-05-03

Gemma Atkinson, Lund University Vasili Hauryliuk, Lund University

https://www.virology.lu.se/affiliated - 2026-05-03

Associate Professor Joakim is an Associate professor at the Department of Translational Medicine, Faculty of Medicine PRINCIPAL INVESTIGATOR

https://www.virology.lu.se/pi-joakim-esbjornsson-phd - 2026-05-03

Principal Investigator, Associate Professor in Virology “What would be easy turned out to be difficult. That is one way of summarising over 30 years of efforts to find a vaccine or a cure for HIV, the virus that causes the disease AIDS. It is this scientific challenge that triggers the researcher Joakim Esbjörnsson.” From “Forskarnas Nyheter”(2017) Joakim Esbjörnsson is an Associate senior lecture

https://www.virology.lu.se/systems-virology/joakim-esbjornsson-phd - 2026-05-03

The Covid-19 pandemic has clearly demonstrated how fast viruses can become a significant threat to global health. Through national and international collaboration, we can improve our readiness for future virus outbreaks.Pandemics and alertness | Lund UniversityLinkedIn_Pandemics_and alertness

https://www.virology.lu.se/pandemics-and-alertness - 2026-05-03

The field of tumor virology has provided groundbreaking insights into the causes of human cancer. In my research at Lund University I focus on I) characterization of human papillomavirus (HPV)-associated mechanisms for disease development and II) use of HPV for prevention of disease.Concerning HPV-associated benign tumors as recurrent laryngeal papilloma, we study de-regulated pathways of the loca

https://www.virology.lu.se/tumor-virology - 2026-05-03

Laryngeal Papilloma Interaction between HPV, respiratory bacteria, and a dysfunctional local immune response may promote laryngeal papilloma.  Although presence of human papillomavirus (HPV)-vaccines, there are new cases of HPV-diseases. Such a disease is laryngeal papilloma (LP) which is a benign tumor that can persist during life and is considered incurable, manifested by obstruction in the resp

https://www.virology.lu.se/tumor-virology/projects - 2026-05-03

Ola Forslund, PILouise Pedersen, Lab technicianTove Wadenius, Lab technicianYlva Lindroth, PhD student

https://www.virology.lu.se/tumor-virology/tumor-virology-team - 2026-05-03

Principal Investigator, Associate Professor in VirologyOla Forslund is a Senior Lecturer in Tumor Virology and Associate Professor in Virology at the Department of Translational Medicine, Medical Faculty at Lund University. Ola received his Ph.D in 1997 at Lund University, and performed postdoctoral studies at Umeå University and as a visiting research fellow at IMVS in Adelaide. From 2000 he was

https://www.virology.lu.se/tumor-virology/ola-forslund-pi - 2026-05-03

Ola Forslund Ola Forslund_LUCRISOla Forslund_PubMed 

https://www.virology.lu.se/tumor-virology/publications - 2026-05-03

Stefan Schwartz UUMagnus Pålsson, LUAastha SobtiYlva LindrothCaroline HellstenSelamawit Mekuria

https://www.virology.lu.se/tumor-virology/collaborators - 2026-05-03

Associate Professor Ola Forslund, Ph.D.Department of Translational MedicineLund UniversitySölvegatan 23B221 85 Lund, SwedenPhone +46 46-17 19 08Mobile +46 70 33 26 950E-mail: ola [dot] forslund [at] med [dot] lu [dot] se (Ola[dot]forslund[at]med[dot]lu[dot]se)

https://www.virology.lu.se/tumor-virology/contact - 2026-05-03

Joakim Esbjörnsson Joakim Esbjörnsson_LUCRISJoakim Esbjörnsson_PubMedReview articles and invited publications in peer-reviewed international journals Esbjörnsson J, Jansson M, Jespersen S, Månsson F, Hønge BL, Lindman J, Medina C, da Silva ZJ, Norrgren H, Medstrand P, Rowland-Jones SL, Wejse C. HIV-2 as a model to identify a functional HIV cure. AIDS Res Ther. 2019 Sep 5;16(1):24. doi: 10.1186/s12

https://www.virology.lu.se/systems-virology/publications - 2026-05-03

There are two types of HIV, HIV-1 and HIV-2, which can lead to AIDS. HIV-1, with global spread, is the more aggressive and infectious virus. The reason for the difference in pathogenesis between HIV-1 and HIV-2 is not yet clear, and neither is the inhibiting effect that HIV-2 has on HIV-1 in dually infected understood. Our research is focused on understanding the interactions between the immune sy

https://www.virology.lu.se/hiv-host-interactions - 2026-05-03

National Cecilia Ahlström-Emanuelsson - Ear, Nose and Throat Diseases, Lund University Jan Albert - Department of Microbiology, Tumor and Cell Biology, Karolinska Institute Anna Karin Pereira Bastos - Ear, Nose and Throat Diseases, Trelleborg Hospital Per Björkman - Clinical infection medicine, Lund University Stefan Freccero - Ear, Nose and Throat Diseases, Trelleborg Hospital Marianne Jansson -

https://www.virology.lu.se/systems-virology/collaborators - 2026-05-03

Studien inriktade sig på de barn som deltagit i TEDDY och utvecklat autoimmun (typ 1) diabetes. Även barn som inte deltagit i TEDDY tillfrågades om de ville vara med i studien. Dessa matchades i ålder och blev "kontroller" och följdes sedan på samma sätt som TEDDY barnen. TEDDY Follow-up studien startade år 2012 och avslutades under 2017.  I studien undersöktes hur länge barnet hade egen produktio

https://www.teddy.lu.se/alla-studier-i-cap/avslutade-studier-i-cap/teddy-follow - 2026-05-03

TEDDY-besöken sker vanligtvis vid hel och halvår, alltså kring födelsedagen och ett emellan. Vid varje besök händer följande: Intervju och frågeformulär Längd och vikt Blodprov Näsprov Urinprov En gång om året, upp till 10 års ålder, registreras TEDDY-deltagarens fysiska aktivitet under en vecka med hjälp av en actigraf. Har deltagaren autoantikroppar fortsätter man denna registrering en gång om å

https://www.teddy.lu.se/att-vara-med-i-teddy/detta-hander-pa-teddy-besoken - 2026-05-03

Actigraf Matdagbok Tånaglar Blodprov Mjölktand Urin- och avföringsprover Intervju och Frågeformulär Näsprov Vattenprov

https://www.teddy.lu.se/att-vara-med-i-teddy/material-som-samlas-till-teddy-studien - 2026-05-03

Vid varje besök på TEDDY tas ett blodprov på deltagaren. Eftersom blodet ska användas till olika analyser behövs flera olika provrör. Provet tas därför venöst, det vill säga från ett kärl i armvecket. Första gången TEDDY-deltagaren lämnade blodprov var han/hon cirka 4 månader gammal. Upp till 4 års ålder var besöken 4 gånger om året och efter 4 år var besöken 2 gånger om året. För de deltagare som

https://www.teddy.lu.se/att-vara-med-i-teddy/material-som-samlas-till-teddy-studien/blodprov - 2026-05-03